Clinical Research Directory
Browse clinical research sites, groups, and studies.
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Sponsor: Altimmune, Inc.
Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Official title: RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-05-15
Completion Date
2026-06
Last Updated
2025-11-19
Healthy Volunteers
No
Conditions
Interventions
Pemvidutide
Pemvidutide 2.4mg
Placebo
Subcutaneous injection
Locations (12)
Altimmune Clinical Study Site
Los Angeles, California, United States
Altimmune Clinical Study Site
Aurora, Colorado, United States
Altimmune Clinical Study Site
New Haven, Connecticut, United States
Altimmune Clinical Study Site
Fort Myers, Florida, United States
Altimmune Clinical Study Site
University Park, Florida, United States
Altimmune Clinical Study Site
North Canton, Ohio, United States
Altimmune Clinical Study Site
Tulsa, Oklahoma, United States
Altimmune Clinical Study Site
Philadelphia, Pennsylvania, United States
Altimmune Clinical Study Site
Providence, Rhode Island, United States
Altimmune Clinical Study Site
Charleston, South Carolina, United States
Altimmune Clinical Study Site
Charlottesville, Virginia, United States
Altimmune Clinical Study Site
Richmond, Virginia, United States